Kevin C Kemp

List of Publications by Year
in descending order

36 papers	1,478 citations	304743 22 h-index	330143 37 g-index
37 all docs	37 docs citations	37 times ranked	2464 citing authors

#	Article	IF	Citations
1	Reduced expression of mitochondrial fumarate hydratase in progressive multiple sclerosis contributes to impaired in vitro mesenchymal stromal cell-mediated neuroprotection. Multiple Sclerosis Journal, 2022, 28, 1179-1188.	3.0	3
2	Abnormal scaffold attachment factor 1 expression and localization in spinocerebellar ataxias and Huntingtonâ€™s chorea. Brain Pathology, 2020, 30, 1041-1055.	4.1	3
3	shRNAâ€mediated PPARÎ± knockdown in human glioma stem cells reduces <i>in vitro</i> proliferation and inhibits orthotopic xenograft tumour growth. Journal of Pathology, 2019, 247, 422-434.	4.5	13
4	Bone marrow transplantation stimulates neural repair in Friedreich's ataxia mice. Annals of Neurology, 2018, 83, 779-793.	5.3	14
5	Aberrant cerebellar Purkinje cell function repaired in vivo by fusion with infiltrating bone marrow-derived cells. Acta Neuropathologica, 2018, 135, 907-921.	7.7	16
6	Reduced cellularity of bone marrow in multiple sclerosis with decreased MSC expansion potential and premature ageing in vitro. Multiple Sclerosis Journal, 2018, 24, 919-931.	3.0	35
7	Reduced neuroprotective potential of the mesenchymal stromal cell secretome with ex vivo expansion, age and progressive multiple sclerosis. Cytotherapy, 2018, 20, 21-28.	0.7	27
8	Dysregulation of Mesenchymal Stromal Cell Antioxidant Responses in Progressive Multiple Sclerosis. Stem Cells Translational Medicine, 2018, 7, 748-758.	3.3	27
9	Mesenchymal Stem Cell-Derived Factors Restore Function to Human Frataxin-Deficient Cells. Cerebellum, 2017, 16, 840-851.	2.5	8
10	Cytokine therapyâ€mediated neuroprotection in a Friedreich's ataxia mouse model. Annals of Neurology, 2017, 81, 212-226.	5.3	26
11	Purkinje cell injury, structural plasticity and fusion in patients with Friedreichâ€™s ataxia. Acta Neuropathologica Communications, 2016, 4, 53.	5.2	36
12	Oxidative injury in multiple sclerosis cerebellar grey matter. Brain Research, 2016, 1642, 452-460.	2.2	19
13	Oxidative stress-related biomarkers in multiple sclerosis: a review. Biomarkers in Medicine, 2016, 10, 889-902.	1.4	49
14	Purkinje Cell Pathology and Loss in Multiple Sclerosis Cerebellum. Brain Pathology, 2015, 25, 692-700.	4.1	39
15	Reductions in kinesin expression are associated with nitric oxideâ€induced axonal damage. Journal of Neuroscience Research, 2015, 93, 882-892.	2.9	23
16	The Use of Mesenchymal Stem Cells for Treating Neurodegenerative Diseases. Stem Cells and Cancer Stem Cells, 2015, , 3-20.	0.1	2
17	Analyzing Cell Fusion Events Within the Central Nervous System Using Bone Marrow Chimerism. Methods in Molecular Biology, 2015, 1313, 165-184.	0.9	1
18	Increased microglial catalase activity in multiple sclerosis grey matter. Brain Research, 2014, 1559, 55-64.	2.2	18

#	Article	IF	Citations
19	Cell fusion in the brain: two cells forward, one cell back. Acta Neuropathologica, 2014, 128, 629-638.	7.7	37
20	Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases. Lancet, The, 2013, 382, 1204-1213.	13.7	54
21	Accumulation of cortical hyperphosphorylated neurofilaments as a marker of neurodegeneration in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 153-161.	3.0	26
22	Changes in Expression of the Antioxidant Enzyme SOD3 Occur Upon Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells In Vitro. Stem Cells and Development, 2012, 21, 2026-2035.	2.1	32
23	Purkinje cell fusion and binucleate heterokaryon formation in multiple sclerosis cerebellum. Brain, 2012, 135, 2962-2972.	7.6	38
24	Human Mesenchymal Stem Cells Increase Anti-oxidant Defences in Cells Derived from Patients with Friedreichâ€™s Ataxia. Cerebellum, 2012, 11, 861-871.	2.5	22
25	Human bone marrow mesenchymal stem cells protect catecholaminergic and serotonergic neuronal perikarya and transporter function from oxidative stress by the secretion of glial-derived neurotrophic factor. Brain Research, 2012, 1431, 86-96.	2.2	50
26	Alkylating chemotherapeutic agents cyclophosphamide and melphalan cause functional injury to human bone marrow-derived mesenchymal stem cells. Annals of Hematology, 2011, 90, 777-789.	1.8	34
27	Neurofilament dot blot assays: Novel means of assessing axon viability in culture. Journal of Neuroscience Methods, 2011, 198, 195-203.	2.5	12
28	Mechanisms of Oxidative Damage in Multiple Sclerosis and a Cell Therapy Approach to Treatment. Autoimmune Diseases, 2011, 2011, 1-11.	0.6	80
29	Mesenchymal Stem Cells Restore Frataxin Expression and Increase Hydrogen Peroxide Scavenging Enzymes in Friedreich Ataxia Fibroblasts. PLoS ONE, 2011, 6, e26098.	2.5	24
30	Chemotherapy-induced mesenchymal stem cell damage in patients with hematological malignancy. Annals of Hematology, 2010, 89, 701-713.	1.8	54
31	Inflammatory Cytokine Induced Regulation of Superoxide Dismutase 3 Expression by Human Mesenchymal Stem Cells. Stem Cell Reviews and Reports, 2010, 6, 548-559.	5.6	74
32	Mesenchymal stem cellâ€secreted superoxide dismutase promotes cerebellar neuronal survival. Journal of Neurochemistry, 2010, 114, 1569-1580.	3.9	107
33	Stem cells in genetic myelin disorders. Regenerative Medicine, 2010, 5, 425-439.	1.7	8
34	Characterization of in vitro expanded bone marrow-derived mesenchymal stem cells from patients with multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 909-918.	3.0	62
35	Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. Stem Cell Research, 2009, 3, 63-70.	0.7	253
36	Bone marrow-derived mesenchymal stem cells. Leukemia and Lymphoma, 2005, 46, 1531-1544.	1.3	151